Skip to main content
. Author manuscript; available in PMC: 2018 Jul 15.
Published in final edited form as: Clin Cancer Res. 2017 Jan 17;23(14):3657–3666. doi: 10.1158/1078-0432.CCR-16-2592

Figure 2.

Figure 2

A. The median KRASG12/G13 copy numbers in urine at baseline (8.6), on therapy (0), and at disease progression (6.9) differed significantly (P = 0.002). B. The median KRASG12/G13 copy numbers in plasma at baseline (488.5), during therapy (11.0), and at disease progression (258.6) also differed significantly (P < 0.001).